Agennix Inc., of Houston, appointed Dalal Murgai regulatory affairs and quality assurance manager.

ArQule Inc., of Medford, Mass., appointed Philippe Bey chief scientific officer and senior vice president of research and development.

BioMarin Pharmaceutical Inc., of Novato, Calif., named John Jost vice president, manufacturing.

Cepheid, of Sunnyvale, Calif., appointed Mike O'Neill director of manufacturing.

Chiron Corp., of Emeryville, Calif., named Joyce Lonergan division vice president of corporate development, and Peder Jensen corporate vice president and head of development.

Dynavax Technologies Corp., of Berkeley, Calif., appointed Philip Haworth vice president, corporate development and strategic planning.

Entelos Inc., of Menlo Park, Calif., named Steve Crothers vice president of biologic model development.

Enzon Inc., of Piscataway, N.J., named to its board of directors David Barlow, president of pharmaceuticals at Sepracor Inc., of Marlborough, Mass.

Hyland Immuno, a Glendale, Calif., division of Baxter Healthcare Corp., named Charlotte Schwab vice president of global business development for its Recombinant Strategic Business Unit.

Immunomedics Inc., of Morris Plains, N.J., named Joop Meijer general manager of its European subsidiary, Immunomedics BV, of Hillegom, the Netherlands.

InterMune Pharmaceuticals Inc., of Palo Alto, Calif., named to its board of directors Nicholas Simon, vice president, business and corporate development at Genentech Inc.

Maxim Pharmaceuticals Inc., of San Diego, appointed to its board of directors Gary Fraschier, chairman of OSI Pharmaceuticals Inc.

Myelos Corp., of San Diego, named Charlotte Clark vice president, business development.

Nabi, of Boca Raton, Fla., named Anna Mack senior director and general counsel, and Mark Smith senior director, finance and chief accounting officer.

Trimeris Inc., of Durham, N.C., appointed the company's founder, Thomas Matthews, to the post of senior vice president of research and development.

UCB Pharma, of Cambridge, Mass., named Thomas Beck president and director, global research of UCB Research Inc.